| P2093 | author name string | Qing Zhang | |
| | Junhui Chen | |
| | Shaobin Wang | |
| | Zhendong Yu | |
| P2860 | cites work | Panobinostat in multiple myeloma | Q88761558 |
| | Belinostat (Beleodaq) for peripheral T-Cell lymphoma | Q95385612 |
| | Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents | Q21198868 |
| | HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling | Q24319032 |
| | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) | Q24681480 |
| | Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma | Q26773334 |
| | Romidepsin for the Treatment of Peripheral T-Cell Lymphoma | Q26785732 |
| | Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review | Q26796449 |
| | Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications | Q26853394 |
| | Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China | Q28070073 |
| | Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting | Q28078806 |
| | The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition | Q28542639 |
| | Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes | Q29398493 |
| | Anticancer activities of histone deacetylase inhibitors | Q29616624 |
| | Clinical Toxicities of Histone Deacetylase Inhibitors | Q31135325 |
| | Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma | Q33375600 |
| | Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma | Q33375694 |
| | FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma | Q33377159 |
| | Vorinostat in solid and hematologic malignancies | Q33385544 |
| | Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma | Q33389625 |
| | Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS) | Q33395173 |
| | Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial | Q33403332 |
| | Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. | Q33405714 |
| | Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma | Q38837680 |
| | Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma | Q38843100 |
| | The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC. | Q38878715 |
| | Histone deacetylases function as a novel potential therapeutic target for cancer | Q38908331 |
| | Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma | Q38910180 |
| | Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer | Q38941457 |
| | The novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-κB. | Q38943920 |
| | A general approach for the development of fluorogenic probes suitable for no-wash imaging of kinases in live cells | Q38944958 |
| | HDACs and HDAC Inhibitors in Cancer Development and Therapy | Q38947405 |
| | Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma. | Q38951433 |
| | Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016). | Q38996526 |
| | Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells | Q38998021 |
| | Targeting histone deacetylases in T-cell lymphoma | Q38998630 |
| | Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells. | Q39005535 |
| | Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma | Q39019103 |
| | Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia | Q39044362 |
| | Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition | Q39253408 |
| | Panobinostat for the management of multiple myeloma | Q38806260 |
| | Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL. | Q38812165 |
| | Panobinostat for the treatment of acute myelogenous leukemia | Q38835113 |
| | A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. | Q39287526 |
| | Antitumor activity of Chidamide in hepatocellular carcinoma cell lines | Q39368032 |
| | CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells | Q39395916 |
| | Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity | Q39443782 |
| | Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells | Q39653684 |
| | Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance | Q39744464 |
| | A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells | Q39754297 |
| | In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma | Q39768627 |
| | Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma | Q39883430 |
| | The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. | Q40050634 |
| | Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma | Q40070617 |
| | Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB. | Q40103966 |
| | Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action | Q40349894 |
| | A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. | Q40504613 |
| | Long-Term Treatment with Romidepsin in Patients with Peripheral T-Cell Lymphoma | Q41038262 |
| | Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells | Q41446518 |
| | The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines | Q41573605 |
| | Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells | Q42081115 |
| | Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2 | Q42152675 |
| | Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China | Q42316356 |
| | Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL | Q42705204 |
| | Vorinostat(SAHA) Promotes Hyper-Radiosensitivity in Wild Type p53 Human Glioblastoma Cells. | Q42974434 |
| | Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene | Q44223669 |
| | The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells | Q44872972 |
| | Significantly increased CD70 up regulation on TEL-AML positive B cell precursor acute lymphoblastic leukemia cells following CD40 stimulation | Q45284467 |
| | Romidepsin and interferon gamma: A novel combination for refractory cutaneous T-cell lymphoma | Q45811417 |
| | A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors | Q46775253 |
| | Incidence and survival patterns of cutaneous T-cell lymphomas in the United States | Q46778060 |
| | Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells | Q47840446 |
| | FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma | Q49132819 |
| | A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation | Q49156055 |
| | Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma. | Q50906490 |
| | BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma | Q51100298 |
| | Chidamide alleviates TGF-β-induced epithelial-mesenchymal transition in lung cancer cell lines. | Q51462451 |
| | Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice | Q52888741 |
| | Bortezomib and panobinostat combination is effective against PTCL | Q53169774 |
| | Histone Deacetylase in Chronic Lymphocytic Leukemia | Q53192790 |
| | Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells | Q53242291 |
| | Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement | Q53738710 |
| | Vorinostat | Q56002311 |
| | Molecule of the month. Vorinostat | Q80259707 |
| | Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies | Q81310348 |
| | Acetylation controls Notch3 stability and function in T-cell leukemia | Q82696715 |
| | Survivin(g) adult T-cell leukemia/lymphoma | Q82728396 |
| | The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome | Q83760743 |
| | DARTs take aim at BiTEs | Q83992646 |
| | Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets | Q85026964 |
| | Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T‐cell lymphoma | Q86603764 |
| | The role of T-cell phenotype and T-cell receptor rearrangement in the diagnosis of T-cell malignancies | Q87272757 |
| | Belinostat: first global approval | Q87609508 |
| | Panobinostat in lymphoid and myeloid malignancies | Q33408889 |
| | Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma | Q33410761 |
| | Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial | Q33412763 |
| | A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma | Q33413857 |
| | A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma | Q33418737 |
| | A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. | Q33419840 |
| | Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma | Q33423854 |
| | Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study | Q33428567 |
| | Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial | Q33428575 |
| | A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients | Q33431457 |
| | A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas | Q33619776 |
| | Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. | Q33800456 |
| | Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells | Q33808800 |
| | Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase | Q34001339 |
| | A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study | Q34084575 |
| | FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity | Q34291658 |
| | Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells | Q34336020 |
| | Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma | Q34434810 |
| | Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation | Q34770008 |
| | Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy | Q34890457 |
| | Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells | Q34994576 |
| | Histone deacetylase inhibition redistributes topoisomerase IIβ from heterochromatin to euchromatin | Q35015901 |
| | Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model | Q35085362 |
| | Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1. | Q35103991 |
| | Histone Deacetylase Inhibitor Belinostat Represses Survivin Expression through Reactivation of Transforming Growth Factor β (TGFβ) Receptor II Leading to Cancer Cell Death | Q35183027 |
| | Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma | Q35186682 |
| | Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents | Q35214924 |
| | Metabolism as a key to histone deacetylase inhibition | Q35661981 |
| | New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat | Q35703714 |
| | Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias | Q35750919 |
| | The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin | Q35890561 |
| | Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death | Q35922012 |
| | Romidepsin for the Treatment of Peripheral T-Cell Lymphoma. | Q36064937 |
| | Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions | Q36066954 |
| | Histone Deacetylase 3 Is Required for Efficient T Cell Development | Q36174093 |
| | Chidamide Inhibits Aerobic Metabolism to Induce Pancreatic Cancer Cell Growth Arrest by Promoting Mcl-1 Degradation | Q36201181 |
| | Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells | Q36203280 |
| | Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma | Q36288249 |
| | A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia. | Q36395421 |
| | Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. | Q36660672 |
| | MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor | Q36850845 |
| | Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma | Q36936514 |
| | Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling | Q37144116 |
| | Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. | Q37192391 |
| | Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma | Q37355651 |
| | Development of vorinostat: current applications and future perspectives for cancer therapy | Q37381104 |
| | Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges | Q37432654 |
| | Clinical studies of histone deacetylase inhibitors. | Q37512917 |
| | Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma. | Q37579991 |
| | Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma | Q37609238 |
| | Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma. | Q37702571 |
| | The biology of HDAC in cancer: the nuclear and epigenetic components | Q37924191 |
| | Belinostat: clinical applications in solid tumors and lymphoma | Q37951994 |
| | Toxicological and metabolic considerations for histone deacetylase inhibitors | Q38071321 |
| | Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors | Q38159410 |
| | Advances in T-cell therapy for ALL. | Q38278981 |
| | Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials | Q38379898 |
| | AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy | Q38558611 |
| | Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes | Q38710509 |
| | Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma | Q38716460 |
| | The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies | Q38717046 |
| | A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes | Q38738628 |
| | Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma | Q38752460 |
| | Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma | Q38757938 |
| | Histone deacetylase inhibitors as immunomodulators in cancer therapeutics | Q38763747 |
| | An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma | Q38765451 |
| | Induction of apoptosis by HBI-8000 in adult T-cell leukemia/lymphoma is associated with activation of Bim and NLRP3. | Q38770098 |
| | Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells. | Q38791801 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | T-cell lymphoma | Q7667896 |
| | targeted therapy | Q492646 |
| | histone deacetylase inhibitors | Q3569101 |
| | peripheral T-cell lymphoma | Q7168693 |
| | Cutaneous T‐cell lymphoma | Q58748290 |
| P304 | page(s) | 424-442 | |
| P577 | publication date | 2019-01-01 | |
| | 2019-01-29 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | International Journal of Medical Sciences | Q10927439 |
| P1476 | title | Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas | |
| P478 | volume | 16 | |